Banc of America Cuts aaiPharma to 'Neutral'

Analyst David Maris says he cut his rating until he has clarity on the company's ongoing review of inventory levels

Shares of aaiPharma (AAII ) plunged after the company says it has become aware of sales abnormalities in its Brethine and Darvocet product lines during the second half of 2003. This will materially affect previously announced guidance for the first quarter and 2004, and the company withdrew guidance.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.